STENTiT, an Eindhoven, The Netherlands-based MedTech company, raised €1.8m in seed funding.
The round was made by NextGen Ventures, Brabant Development Agency (BOM) and the Ten Cate Investment Company.
The company intends to use the funds to facilitate further pre-clinical development and batch production of a regenerative stent for peripheral indications.
Led by Bart Sanders, CEO, STENTiT is a medical device company bringing a novel class of regenerative endovascular implants for the treatment of cardiovascular diseases. Using a catheter-based approach, these devices provide the ability to restore arteries without the need for an invasive surgical intervention. The aim is to ultimately restore the affected blood vessel from the inside out to provide a lifelong solution.
It is a medical device spin-off company from the Dutch Eindhoven University of Technology.
FinSMEs
25/04/2022